Flurbiprofen (BTS 18 322, 2-(2-fluoro-4-biphenylyl) propionic acid) is a member of the phenylalkanoic acid series. It differs from its predecessors (ibuprofen, ibufenac) in having a biphenyl nucleus ( Fig. 1 ), but, like them, possesses analgesic, anti-inflammatory, and antipyretic properties. In animal experiments it has been found to be much more potent than ibuprofen, acetylsalicylic acid, and other nonsteroidal anti-inflammatory drugs. It has been shown to be devoid of glucocorticoid activity and has no demonstrable effect on the adrenal cortex (Adams and McCullough, 1971) . In this paper we report preliminary studies on flurbiprofen in patients with rheumatoid arthritis, including the results of a double-blind cross-over trial.
Materials and methods Clinical pharmacological studies
These were conducted on 28 in-patients with 'definite' rheumatoid arthritis as defined by the diagnostic criteria of the American Rheumatism Association (Ropes, Bennett, Cobb, Jacox, and Jessar, 1959) . The dosage schedules are summarized in Table I . All but two of the patients had positive tests for rheumatoid factor and all but one had articular erosions on x-ray examination of the joints. Three of the patients were males. The mean age of the 28 patients was 55 years (range of 22 to 79). All were Caucasian. Every patient was informed about the nature of the drug and consent was obtained before it was administered. All other antirheumatic therapy was stopped the day before flurbiprofen was commenced.
In addition to age and sex, the following clinical parameters were recorded: height, weight, duration of arthritis, (Steinbrocker, Traeger, and Batterman, 1949) Full blood counts were performed before, during, and at the end of treatment with flurbiprofen. Liver function tests, serum electrolytes, blood urea, serum uric acid, serum creatinine, serum proteins, fasting blood sugar, serum cholesterol, serum calcium and phosphorus, and urine analysis were performed before and at the end of treatment in all cases. In addition, serum protein-bound iodine (11 patients), T3 resin uptake (11 patients), bromsulphthalein retention (3 patients), faecal fat (11 patients), xylose absorption (8 patients), serum vitamin B52 (10 patients), and serum folate (10 patients) were measured. Flurbiprofen blood levels were measured in three patients taking 15 mg. twice a day, in four taking 20 mg. twice a day, and in four taking 25 mg. twice a day. On the 1st day of therapy a blood sample was taken before the first dose of flurbiprofen was administered and thereafter at 1i, 3, 6, and 12 hrs. The 12-hr. sample was taken before the second dose of the drug was given. On the 10th day (i.e. the last day of therapy), a repeat of the procedure for the 1st day was carried out. Blood samples were also taken on the momings ofthe 2 days followingcessation oftherapy to determine the persistence of the drug.
Flurbiprofen was measured by gas-liquid chromatography by Dr. W. Dickinson at the Chemical Sciences Laboratories of The Boots Company Ltd. (Dickinson, 1971 The circumference of the proximal interphalangeal joints of the fingers and interphalangeal joint of the thumb were measured on each hand using the Geigy apparatus. An articular index of joint tenderness was estimated as described by Ritchie, Boyle, McInnes, Jasani, Dalakos, Grieveson, and Buchanan (1968) . In addition, the pair of most severely involved large joints was assessed for pain, tenderness, swelling, stiffness, and heat, each item being scored on a 0 to 3 basis (0 = nil; 1 = slight; 2 = moderate; 3 = severe). The patient's and physician's assessment ofthe patient's progress were recorded, the scoring being on a 1 to 5 scale (1 = much worse, 2 = worse, 3 = no change, 4= better, 5 = much better). The erythrocyte sedimentation rate (Westergren method) was measured at the end of each treatment week.
Those aspects ofthe patient's assessment which required an estimate of a subjective symptom were performed in a standard manner. For example, subjective impression of pain was elicited by the question: ' Full blood count, standard liver function tests, serum uric acid and urea, and urine analysis were performed before entry into the trial and at the end of each treatment week. No patient with evidence of gross hepatic or renal disease was admitted to the trial.
In twelve patients, radioactive technetium studies were performed at the end of each treatment week. A slight modification of the procedure described by Dick and his colleagues was used (Dick, Neufeld, Prentice, Woodbum, Whaley, Nuki, and Buchanan, 1970; Dick, Deodhar, Provan, Nuki, and Buchanan, 1971) . Approximately 200 ,uCi of 99mTc (as sodium pertechnetate) was standardized by counting for 2 min at 30 cm., using a thalliumactivated sodium iodide scintillation crystal and photomultiplier. The pulses were fed through a pulse-height analyser (EKCO M5050) and digital rate-meter (EKCO M5183A) and read out from the latter. Thereafter, the dose was injected intravenously into an antecubital vein, great care being taken to ensure no extravasation of the dose at the time of injection. At 15 and 90 mins after injection, counting was performed over a wrist and a knee (always in that order and always on the same side for a given patient). Each count lasted for 2 mins. The scintillation counter was positioned 2-5 cm. above the joint being examined. In the case of the wrist, the counter was aligned with a point on the dorsum midway between the radial and the ulnar borders at the level of the distal end of the ulnar styloid, and in the case of the knee, with the midpoint of the upper pole of the patella. Counts over the joints were expressed as a percentage ofthe dose.
Results
Clinical pharmacological studies None of the 28 patients developed any abnormality in any of the haematological or biochemical tests during or after flurbiprofen therapy. In those patients in whom xylose absorption was measured, a consistent increase in urinary xylose was noted after treatment. Two patients had subnormal figures before treatment, but in both cases normal values were obtained after treatment (Table II) . The mean value before treatment was 1 1 ± 0-2 g and after was 1 9 ± 02 g: the difference is highly significant by the paired 't' Mean ± S.E.M. 1.1 ± 0-2t 1-9 ± 0.2t test (t = 677; P <0001). No patient showed any significant deterioration in his arthritis and the severity of the arthritis did not appear to influence the reaction to the drug in any way. Two patients volunteered side-effects, both while receiving 10 mg. flurbiprofen three times a day. One patient reported 'hissing noises' in her ears which began on the 2nd day oftherapy and persisted through to the 6th day when therapy was discontinued. The level of flurbiprofen, estimated in a sample of this patient's serum withdrawn 2 hrs after the first dose on the 4th day of treatment, was found to be 0 3 p,g./ml.
The 'hissing' had completely disappeared 4 days after therapy had ceased. The second patient reported 'buzzing in the head' which began on the 3rd day of therapy. Flurbiprofen was discontinued on Day 5 and placebo capsules substituted. 'Buzzing' continued on Days 6 and 7, but had begun to diminish on Day 8 and had disappeared by Day 10. In both these cases, detailed otological studies (including audiograms and tests of vestibular function) were completely negative. No other side-effects were noted.
Serum levels of flurbiprofen are shown in Table III and illustrated in Fig. 2 .
Clinical trial
The results of the double-blind cross-over trial are shown in Table IV (overleaf). Of the twenty patients who entered the trial, three had to be withdrawn: one experienced nausea and vomiting while receiving the active drug, the second was found to have a urinary tract infection and raised blood urea, and the third developed an urticarial skin rash while on placebo. Table IV shows that flurbiprofen was significantly better than placebo in the following assessments: subjective impression of pain, severity and duration of morning stiffness, grip strength, articular index, doctor's assessment of progress, and patient's advanced for the two cases of possible ototoxicity which occurred early in these studies. Subsequent patients received much higher dosages of the drug, but none of them reported any symptoms referable to the inner ear. In addition, the serum level of flurbiprofen measured in one of the patients with tinnitus was very much lower than some of those recorded for asymptomatic patients. Laboratory investigations did not reveal any adverse effect of flurbiprofen on haemopoiesis, hepatic, renal, or thyroid function, uric acid metabolism, glucose tolerance, or intestinal absorption. The short-term nature of these studies must again be emphasized, however. Three parameters of intestinal function (faecal fat, serum vitamin B12, and serum folate) were unchanged by the drug, but one, namely xylose absorption, appeared to be enhanced. The reason for this is not clear, but it may be artefactual. Some commonly-used antirheumatic drugs, namely aspirin and indomethacin, have been shown to affect the xylose test adversely (Kendall, Nutter, and Hawkins, 1971) , and it may be that the apparent enhancement of xylose absorption by flurbiprofen merely represents recovery from the deleterious effects of a previous drug. On the other hand, a positive effect of flurbiprofen on the intestinal absorption or renal handling of xylose cannot be discounted without further study.
Serum levels ofthe drug were measured in too small a number of patients for any firm conclusions to be drawn and the suggestion of accumulation in the blood from the Day 10 levels is within the limits of error of the experimental technique used. However further studies are needed to answer this problem fully.
The double-blind trial showed flurbiprofen to be significantly better than placebo in most of the parameters measured and flurbiprofen may be regarded as a useful analgesic for rheumatoid arthritis. Two assessments that failed to show significant change were joint size and special joint score. The former may have failed to alter because of the long duration of disease in many of the patients studied, who therefore probably had irreversible structural changes in the joints measured. Special joint score concentrates on a pair of severely-involved largejoints. It was sometimes difficult to find a suitable pair ofjoints in patients who were selected on the basis of overall severity of the disease, and this assessment is thus probably best reserved for studies of specific joints. Those measurements which may be considered indices of inflammation (99mTc uptake and erythrocyte sedimentation rate) were also unchanged after a week on the active drug. That 99mTc uptake is influenced by anti-inflammatory therapy has been shown conclusively by measurements of uptake before and after intra-articular corticosteroid injections into rheumatoid arthritic knees (Dick and others, 1970) . It may be that time in excess of one week is necessary for the development of a demonstrable anti-inflammatory effect, and long-term studies will be needed to clarify this point.
Summary
Preliminary studies of a new drug, flurbiprofen, are presented. When used on a short-term basis in patients with rheumatoid arthritis it appeared to be well-tolerated and non-toxic. A double-blind crossover trial showed the drug to be significantly superior to placebo in most of the assessment indices. Further, more prolonged, studies are warranted. 
